Alpha Tau Medical Ltd. - Ordinary Shares (NQ:DRTS)

3.650 -0.170 (-4.45%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 24, 2025 Add to My Watchlist

Price and Volume

Volume	43,298
Open	3.850
Bid (Size)	3.200 (1,000)
Ask (Size)	5.110 (500)
Prev. Close	3.820
Today's Range	3.650 - 3.850
52wk Range	2.300 - 4.690
Shares Outstanding	68,575,397
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 22, 2025

Via Benzinga

Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness

October 21, 2025

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Performance

YTD	+17.7%	+17.7%
1 Month	-12.3%	-12.3%
3 Month	+13.7%	+13.7%
6 Month	+18.9%	+18.9%
1 Year	+44.3%	+44.3%

More News

Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial

September 02, 2025

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Expert Ratings for Alpha Tau Medical ↗

December 15, 2023

Via Benzinga

Alpha Tau Stock Rallies To 3-Month High On Smaller-Than-Feared Q1 Loss: Retail Sentiment Stays Bearish ↗

May 20, 2025

Via Stocktwits

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

April 28, 2025

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

April 02, 2025

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Q1 Virtual Investor Summit: On-Demand Presentations Now Live

March 18, 2025

Via ACCESS Newswire

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

February 24, 2025

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease

February 03, 2025

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

January 27, 2025

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

December 18, 2024

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

December 17, 2024

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

October 21, 2024

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Treats First Patient with Recurrent Lung Cancer

October 10, 2024

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC

September 20, 2024

From Alpha Tau Medical Ltd.

Via GlobeNewswire

DRTS Stock Earnings: Alpha Tau Medical Beats EPS for Q2 2024 ↗

August 14, 2024

Via InvestorPlace

Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers

June 25, 2024

From Alpha Tau Medical Ltd.

Via GlobeNewswire

DRTS Stock Earnings: Alpha Tau Medical Beats EPS for Q1 2024 ↗

May 20, 2024

Via InvestorPlace

Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer

May 13, 2024

From Alpha Tau Medical Ltd.

Via GlobeNewswire

DRTS Stock Earnings: Alpha Tau Medical Beats EPS for Q4 2023 ↗

March 07, 2024

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

January 10, 2024

Via Benzinga

Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 20, 2023

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer

November 28, 2023

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer

November 20, 2023

From Alpha Tau Medical Ltd.

Via GlobeNewswire

Frequently Asked Questions

Is Alpha Tau Medical Ltd. - Ordinary Shares publicly traded?

Yes, Alpha Tau Medical Ltd. - Ordinary Shares is publicly traded.

What exchange does Alpha Tau Medical Ltd. - Ordinary Shares trade on?

Alpha Tau Medical Ltd. - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Alpha Tau Medical Ltd. - Ordinary Shares?

The ticker symbol for Alpha Tau Medical Ltd. - Ordinary Shares is DRTS on the Nasdaq Stock Market

What is the current price of Alpha Tau Medical Ltd. - Ordinary Shares?

The current price of Alpha Tau Medical Ltd. - Ordinary Shares is 3.650

When was Alpha Tau Medical Ltd. - Ordinary Shares last traded?

The last trade of Alpha Tau Medical Ltd. - Ordinary Shares was at 11/24/25 04:00 PM ET

What is the market capitalization of Alpha Tau Medical Ltd. - Ordinary Shares?

The market capitalization of Alpha Tau Medical Ltd. - Ordinary Shares is 250.30M

How many shares of Alpha Tau Medical Ltd. - Ordinary Shares are outstanding?

Alpha Tau Medical Ltd. - Ordinary Shares has 250M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.